Details for Patent: 6,965,027
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which drugs does patent 6,965,027 protect, and when does it expire?
Patent 6,965,027 protects XELJANZ XR and XELJANZ and is included in two NDAs.
This patent has thirty-four patent family members in twenty-nine countries.
Summary for Patent: 6,965,027
Title: | Crystalline 3-{4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1 -yl}-3-oxo-propionitrile citrate |
Abstract: | This invention relates to novel amorphous and crystallline forms of 3-{(3R,4R)-4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-pip eridin-1-yl}-3-oxo-propionitrile mono citrate salt, useful as inhibitors of protein kinases, and to their methods of preparation. |
Inventor(s): | Flanagan; Mark E. (Gales Ferry, CT), Li; Zheng J. (Quaker Hill, CT) |
Assignee: | Pfizer Inc. (New York, NY) |
Application Number: | 10/310,078 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 6,965,027 |
Patent Claim Types: see list of patent claims | Compound; Process; |
Drugs Protected by US Patent 6,965,027
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pfizer | XELJANZ XR | tofacitinib citrate | TABLET, EXTENDED RELEASE;ORAL | 208246-001 | Feb 23, 2016 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | ||||
Pfizer | XELJANZ XR | tofacitinib citrate | TABLET, EXTENDED RELEASE;ORAL | 208246-002 | Dec 12, 2019 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | ||||
Pf Prism Cv | XELJANZ | tofacitinib citrate | TABLET;ORAL | 203214-001 | Nov 6, 2012 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | ||||
Pf Prism Cv | XELJANZ | tofacitinib citrate | TABLET;ORAL | 203214-002 | May 30, 2018 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 6,965,027
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Argentina | 037635 | See Plans and Pricing | |||
Austria | 497962 | See Plans and Pricing | |||
Australia | 2002348857 | See Plans and Pricing | |||
Brazil | 0214761 | See Plans and Pricing | |||
Canada | 2469350 | See Plans and Pricing | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |